Cassava Sciences shares rise 11.03% premarket after director buys 8,600 shares for $24,940.

Cassava Sciences surged 11.03% in premarket trading following a significant insider purchase by Director Robert Eugene Anderson Jr., who acquired 8,600 shares at $2.90 per share, totaling $24,940. This transaction, disclosed on November 24, 2025, signals strong confidence in the company’s prospects amid ongoing clinical trials for its Alzheimer’s treatment, Simufilam. The move aligns with broader executive optimism, including CEO Richard Barry’s earlier purchase of 150,000 shares in November, which previously drove a 12.1% intraday gain. Insider buying, particularly by board members and leadership, often reflects strategic conviction and can bolster investor sentiment, especially in high-risk, clinical-stage biopharma firms like Cassava Sciences. The premarket rally underscores market responsiveness to such signals of internal support.